Catalyst Pharmaceuticals Inc
CPRX21.370USD
+0.250+1.18%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
2.61BMarktkapitalisierung
13.21KGV TTM
mehr Informationen über Catalyst Pharmaceuticals Inc Unternehmen
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.
Unternehmensinformationen
BörsenkürzelCPRX
Name des UnternehmensCatalyst Pharmaceuticals Inc
IPO-datumNov 08, 2006
CEOMr. Richard J. (Rich) Daly
Anzahl der mitarbeiter181
WertpapierartOrdinary Share
GeschäftsjahresendeNov 08
Addresse355 Alhambra Circle
StadtCORAL GABLES
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl33134
Telefon13055292522
Websitehttps://catalystpharma.com/
BörsenkürzelCPRX
IPO-datumNov 08, 2006
CEOMr. Richard J. (Rich) Daly
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Patrick James Mcenany
Mr. Patrick James Mcenany
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
4.28M
-4.46%
Dr. Steven R. Miller, Ph.D.
Dr. Steven R. Miller, Ph.D.
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
949.66K
--
Mr. Donald A. Denkhaus
Mr. Donald A. Denkhaus
Independent Director
Independent Director
495.08K
--
Dr. David S. Tierney, M.D.
Dr. David S. Tierney, M.D.
Independent Director
Independent Director
355.62K
--
Mr. Richard J. (Rich) Daly
Mr. Richard J. (Rich) Daly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
199.76K
-25.95%
Mr. Brian D. Elsbernd, J.D.
Mr. Brian D. Elsbernd, J.D.
Chief Compliance Officer, Chief Legal Officer
Chief Compliance Officer, Chief Legal Officer
188.56K
--
Dr. Gary Ingenito, M.D., Ph.D.
Dr. Gary Ingenito, M.D., Ph.D.
Chief Medical Officer and Regulatory Officer
Chief Medical Officer and Regulatory Officer
68.87K
--
Dr. Preethi Sundaram, Ph.D.
Dr. Preethi Sundaram, Ph.D.
Chief Strategy Officer
Chief Strategy Officer
41.08K
-8.72%
Ms. Molly Harper
Ms. Molly Harper
Lead Independent Director
Lead Independent Director
6.75K
--
Ms. Tamar Thompson
Ms. Tamar Thompson
Independent Director
Independent Director
1.41K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Patrick James Mcenany
Mr. Patrick James Mcenany
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
4.28M
-4.46%
Dr. Steven R. Miller, Ph.D.
Dr. Steven R. Miller, Ph.D.
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
949.66K
--
Mr. Donald A. Denkhaus
Mr. Donald A. Denkhaus
Independent Director
Independent Director
495.08K
--
Dr. David S. Tierney, M.D.
Dr. David S. Tierney, M.D.
Independent Director
Independent Director
355.62K
--
Mr. Richard J. (Rich) Daly
Mr. Richard J. (Rich) Daly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
199.76K
-25.95%
Mr. Brian D. Elsbernd, J.D.
Mr. Brian D. Elsbernd, J.D.
Chief Compliance Officer, Chief Legal Officer
Chief Compliance Officer, Chief Legal Officer
188.56K
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
13.46%
The Vanguard Group, Inc.
6.95%
State Street Global Advisors (US)
4.53%
McEnany (Patrick James)
3.51%
Deerfield Management Company, L.P.
2.81%
Other
68.75%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
13.46%
The Vanguard Group, Inc.
6.95%
State Street Global Advisors (US)
4.53%
McEnany (Patrick James)
3.51%
Deerfield Management Company, L.P.
2.81%
Other
68.75%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
43.94%
Investment Advisor/Hedge Fund
24.40%
Hedge Fund
8.56%
Individual Investor
6.05%
Research Firm
4.41%
Pension Fund
1.27%
Bank and Trust
0.44%
Family Office
0.17%
Sovereign Wealth Fund
0.10%
Other
10.67%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
675
109.00M
89.36%
-4.26M
2025Q1
693
109.47M
89.76%
-3.79M
2024Q4
658
108.09M
89.06%
-2.57M
2024Q3
628
104.82M
88.36%
-8.18M
2024Q2
597
106.41M
90.13%
-15.99M
2024Q1
590
105.68M
89.66%
-4.79M
2023Q4
569
93.52M
87.71%
-15.08M
2023Q3
548
90.12M
84.55%
-19.61M
2023Q2
542
91.66M
86.51%
-22.59M
2023Q1
518
97.83M
92.70%
-11.38M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
16.42M
13.46%
-409.06K
-2.43%
Mar 31, 2025
The Vanguard Group, Inc.
8.47M
6.95%
+64.49K
+0.77%
Mar 31, 2025
State Street Global Advisors (US)
5.53M
4.53%
-266.12K
-4.59%
Mar 31, 2025
McEnany (Patrick James)
4.28M
3.51%
-200.00K
-4.46%
Jun 09, 2025
Deerfield Management Company, L.P.
3.42M
2.81%
+289.14K
+9.23%
Mar 31, 2025
Renaissance Technologies LLC
2.96M
2.42%
+250.20K
+9.25%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.77M
2.27%
+100.08K
+3.75%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.19M
1.79%
-825.61K
-27.40%
Mar 31, 2025
Fundsmith LLP
2.15M
1.76%
+2.15M
--
Mar 31, 2025
Goldman Sachs & Company, Inc.
1.77M
1.45%
+371.01K
+26.53%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Neuroscience and Healthcare ETF
3.69%
Tema Neuroscience and Mental Health ETF
2.92%
Invesco Biotechnology & Genome ETF
2.32%
Invesco S&P SmallCap 600 GARP ETF
2.01%
Invesco S&P SmallCap Health Care ETF
1.78%
AAM Sawgrass US Small Cap Quality Growth ETF
1.65%
Invesco Dorsey Wright Healthcare Momentum ETF
1.64%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.56%
Janus Henderson Small Cap Growth Alpha ETF
1.52%
Janus Henderson Small/Mid Cap Growth Alpha ETF
1.44%
Mehr Anzeigen
iShares Neuroscience and Healthcare ETF
Anteil3.69%
Tema Neuroscience and Mental Health ETF
Anteil2.92%
Invesco Biotechnology & Genome ETF
Anteil2.32%
Invesco S&P SmallCap 600 GARP ETF
Anteil2.01%
Invesco S&P SmallCap Health Care ETF
Anteil1.78%
AAM Sawgrass US Small Cap Quality Growth ETF
Anteil1.65%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil1.64%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Anteil1.56%
Janus Henderson Small Cap Growth Alpha ETF
Anteil1.52%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Anteil1.44%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
